FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of November, 2010
Commission File Number: 000-51440
CHINA MEDICAL
TECHNOLOGIES, INC.
(Translation of registrants name into English)
No. 24 Yong Chang North Road
Beijing Economic-Technological Development Area
Beijing 100176
Peoples Republic of China
(Address of principal executive offices)
Indicate by check mark whether
the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes
¨
No
x
If Yes is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): 82- N/A
CHINA MEDICAL TECHNOLOGIES, INC.
Form 6-K
TABLE OF CONTENTS
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
CHINA MEDICAL TECHNOLOGIES, INC.
|
|
|
By:
|
|
/
S
/ T
AKYUNG
(S
AM
)
T
SANG
|
Name:
|
|
Takyung (Sam) Tsang
|
Title:
|
|
Chief Financial Officer
|
Date:
November 18, 2010
Exhibit 99.1
China Medical Technologies Reports Second Fiscal Quarter Financial Results
Beijing, China, November 17, 2010 - China Medical Technologies, Inc. (the Company) (Nasdaq: CMED), a leading China-based advanced
in-vitro diagnostic (IVD) company, today announced its unaudited financial results for the second fiscal quarter ended September 30, 2010 (2Q FY2010).
2Q FY2010 Highlights
|
|
Revenues increased by 21.5% year-over-year to RMB201.8 million (US$30.2 million).
|
|
|
Non-GAAP net income, as defined below, increased 270.1% year-over-year to RMB65.4 million (US$9.8 million).
|
|
|
Non-GAAP diluted earnings per ADS*, as defined below, increased 273.1% year-over-year to RMB2.50 (US$0.37).
|
|
|
Adjusted EBITDA, as defined below, increased 62.6% year-over-year to RMB116.3 million (US$17.4 million).
|
|
|
Net cash generated from operations was RMB67.3 million (US$10.1 million).
|
Outlook for 3Q FY2010
|
|
Target revenues are expected to be not less than RMB220.0 million (US$32.9 million), representing a year-over-year increase of not less than 27.7%.
|
|
|
Target non-GAAP net income is expected to be not less than RMB74.0 million (US$11.1 million), representing a year-over-year increase of not less than
62.2%.
|
|
|
Target non-GAAP diluted earnings per ADS* is expected to be not less than RMB2.82 (US$0.42), representing a year-over-year increase of not less than
62.1%.
|
Outlook for FY2010
|
|
Target revenues are expected to be not less than RMB846.0 million (US$126.4 million), representing a year-over-year increase of not less than 17.0%.
The year-over-year increase of annual revenues for FY2010 is lower than that of 3Q FY2010 because of the 10.9% year-over-year decrease in quarterly revenues of 1Q FY2010.
|
|
|
Target non-GAAP net income is expected to be not less than RMB280.0 million (US$41.9 million), representing a year-over-year increase of not less than
49.5%.
|
|
|
Target non-GAAP diluted earnings per ADS* is expected to be not less than RMB10.69 (US$1.60), representing a year-over-year increase of not less than
49.9%.
|
The above targets are based on the Companys current views on the operating and market conditions, which are
subject to change.
*
|
One American Depositary Share (ADS) = 10 ordinary shares
|
See Non-GAAP Measure Disclosures below, where the impact of certain items on reported results is discussed.
We are pleased to see the
commencement of contribution from sales of HPV-DNA chips which are expected to become another main revenue stream and an important growth driver in addition to our FISH business during the next few years. We have received strong interest in our SPR
equipment from many of our top tier hospital customers and significant purchase orders on our chips from hospitals which have used our chips for their patients on a regular basis. We expect substantial growth on sales of our chips in upcoming
quarters. In addition, our FISH business continued its growth momentum and our ECLIA business has resumed year-over-year growth, commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company.
2Q FY2010 Unaudited Financial Results
The Company reported revenues of RMB201.8 million (US$30.2 million) for 2Q FY2010, representing a 21.5% increase from the corresponding period of FY2009.
The Companys revenues are currently generated from two segments, molecular diagnostic systems and immunodiagnostic systems. The
molecular diagnostic system segment includes FISH products and SPR products while the immunodiagnostic system segment consists of ECLIA products.
Molecular diagnostic system sales for 2Q FY2010 were RMB118.3 million (US$17.7 million), representing a 32.6% increase from the corresponding period of FY2009. The year-over-year increase was primarily
due to the increase in usage of the Companys FISH probes by existing and new hospital customers served by the Companys direct sales personnel as well as the sales of SPR-based HPV-DNA chips of RMB3.8 million (US$0.6 million) to hospitals
during 2Q FY2010.
Immunodiagnostic system sales for 2Q FY2010 were RMB83.5 million (US$12.5 million), representing an 8.7% increase from the
corresponding period of FY2009. The year-over-year increase was primarily due to the increase in sales of the Companys ECLIA reagent kits to existing and new distributors.
Gross margin was 55.2% for 2Q FY2010 which decreased year-over-year from 65.4% for the corresponding period of FY2009. Due to the commencement of sales of HPV-DNA chips, the amortization of SPR intangible
assets amounted to RMB27.3 million (US$4.1 million) was classified from operating expenses to cost of revenues starting from 2Q FY2010. The year-over-year decrease in gross margin was primarily due to this change in classification. The gross margin
for 2Q FY2010 would be 68.6% without this change in classification of expense.
Research and development expenses were RMB10.9 million (US$1.6
million) for 2Q FY2010, representing a 14.5% year-over-year increase. The year-over-year increase was primarily due to product research and development for FISH probes and SPR chips.
Sales and marketing expenses were RMB21.5 million (US$3.2 million) for 2Q FY2010, representing a 23.2% year-over-year increase. The year-over-year increase was primarily due to the increase in direct
sales efforts for molecular diagnostic systems.
General and administrative expenses were RMB25.0 million (US$3.7 million) for 2Q FY2010,
representing a 44.5% year-over-year decrease. The year-over-year decrease was primarily due to no cost of independent internal investigation and lower allowance for doubtful accounts for 2Q FY2010.
Interest expense on convertible notes was RMB32.0 million (US$4.8 million) for 2Q FY2010. As of September 30, 2010, the Companys outstanding
convertible notes of US$135 million and US$248 million bear interest at 3.5% and 4% per annum, respectively, and will mature in November 2011 and August 2013, respectively.
Interest expense on amortization of convertible notes issuance costs was RMB3.9 million (US$0.6 million) for 2Q FY2010.
Interest expense on amortization of
share lending costs was RMB2.5 million (US$0.4 million) for 2Q FY2010.
Income tax expense was RMB21.8 million (US$3.3 million) for 2Q FY2010.
The significant income tax expense was primarily because certain expenses of the Company such as stock compensation expense, amortization of acquired intangible assets and interest expense of convertible notes were not deductible for income tax
purpose. In addition, the Company was required to accrue for withholding income tax on distributable earnings generated in China during 2Q FY2010.
Net loss was RMB2.9 million (US$0.4 million) for 2Q FY2010, representing a 94.1% decrease from the corresponding period of FY2009. The significant year-over-year decrease in net loss was primarily due to
growth in molecular diagnostic system sales and recovery from immunodiagnostic system sales.
Non-GAAP net income, as defined below, was
RMB65.4 million (US$9.8 million) for 2Q FY2010, representing a 270.1% increase from the corresponding period of FY2009.
Earnings before
interest, taxes, depreciation and amortization (EBITDA) was RMB107.1 million (US$16.0 million) for 2Q FY2010, representing a 66.8% increase from the corresponding period of FY2009.
Adjusted EBITDA, which excludes stock compensation expense and gain on purchase of convertible notes from EBITDA, was RMB116.3 million (US$17.4 million)
for 2Q FY2010, representing a 62.6% increase from the corresponding period of FY2009.
Stock compensation expense for 2Q FY2010 was RMB9.2
million (US$1.4 million), of which RMB0.1 million was allocated to cost of revenues, RMB1.1 million to research and development expenses, RMB0.2 million to sales and marketing expenses and RMB7.8 million to general and administrative expenses. The
Company approved the grant of 2,100,000 restricted stock, equivalent to 210,000 ADSs, to directors, officers and certain employees on November 5, 2010. The restricted stock vests at the end of a three-year period.
Amortization of acquired intangible assets for 2Q FY2010 was RMB49.4 million (US$7.4 million) which was all allocated to cost of revenues.
As of September 30, 2010, the Companys cash and cash equivalents was RMB805.9 million (US$120.5 million). Net cash generated from operating
activities for 2Q FY2010 was RMB67.3 million (US$10.1 million). Net cash used in investing activities for 2Q FY2010 was RMB1.2 million (US$0.2 million). There was no financing activity for 2Q FY2010.
As of September 30, 2010, the Companys net accounts receivable was RMB333.1 million (US$49.8 million), representing an increase of 7.0% from
the balance at June 30, 2010.
For the convenience of readers, certain RMB amounts have been translated into U.S. dollars at the rate of
RMB6.6905 to US$1.00, the noon buying rate in New York City for cable transfers of RMB per U.S. dollar as set forth in the H.10 weekly statistical release of the Federal Reserve Board, as of Thursday, September 30, 2010. No representation is
made that the RMB amounts could have been or could be converted into U.S. dollars at that rate or at any other rate on September 30, 2010 or at any other dates.
Update on Receivable from Chengxuan
The receivable of US$30 million from Chengxuan, one of
the Companys major shareholders and owned by Mr. Xiaodong Wu, is due on December 31, 2010 which relates to the sale of the Companys HIFU business to Chengxuan. Chengxuan made an early payment of US$8 million to the Company in
November 2010 and has indicated to the Company that the remaining amount will be paid on or before December 31, 2010.
Non-GAAP Measure Disclosures
The Company provides gross profit, operating income, net income, earnings per ADS, EBITDA and adjusted EBITDA on a Non-GAAP basis to
enable investors to better assess the Companys operating performance. The Non-GAAP measures described by the Company are reconciled to the corresponding GAAP measures in the exhibit below titled Reconciliations of GAAP measures to
Non-GAAP measures.
The Company reported for 2Q FY2010 and provided estimates of net income and diluted earnings per ADS for 3Q FY2010
and full year FY2010 on a Non-GAAP basis. Each of the terms used by the Company is defined as follows:
|
|
Non-GAAP gross profit
represents gross profit reported in accordance with GAAP, adjusted for the effects of stock compensation expense and
amortization of acquired intangible assets.
|
|
|
Non-GAAP operating income
represents operating income reported in accordance with GAAP, adjusted for the effects of stock compensation expense
and amortization of acquired intangible assets.
|
|
|
Non-GAAP net income
represents net income reported in accordance with GAAP, adjusted for the effects of stock compensation expense, amortization
of acquired intangible assets, non-cash interest expense of convertible notes, non-cash interest expense for amortization of share lending costs and gain on purchase of convertible notes.
|
|
|
Non-GAAP earnings per ADS
represents Non-GAAP net income divided by the weighted average number of ADSs used in computing basic and diluted
earnings per ADS in accordance with GAAP.
|
|
|
EBITDA
represents net income reported in accordance with GAAP, adjusted for the effects of interest income, interest expenses, income tax
expense, depreciation as well as amortization of acquired intangible assets.
|
|
|
Adjusted EBITDA
represents EBITDA adjusted for the effects of stock compensation expense and gain on purchase of convertible notes.
|
Non-GAAP financial measures are used by the Company in its financial and operating decision-making because management
believes they reflect the Companys ongoing business in a manner that allows meaningful period-to-period comparison. The Companys management believes that these non-GAAP financial measures provide useful information to investors and
others in understanding and evaluating the Companys current operating performance and future prospects in the same manner as management does, if they so choose.
The presentation of this additional financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. For
a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures, please see the financial information included with this earnings announcement.
Conference Call
The Companys senior management team will host an earnings conference
call at 8:00 a.m. U.S. Eastern Time on November 17, 2010 (or 9:00 p.m. Beijing/Hong Kong time on the same date) to discuss the results following this earnings announcement.
The dial-in details for the live
conference call are as follows:
|
|
U.S. Toll Free Number 1-800-591-6923
|
|
|
International Dial-in Number 1-617-614-4907
|
Passcode: CMEDCALL
A live webcast of the conference call will be available on
http://ir.chinameditech.com
.
A replay of this webcast will be available for one month on this website.
A telephone replay of the call will be available after the conclusion of the conference call through 10:00 a.m. U.S. Eastern Time on November 18,
2010.
The dial-in details for the replay are as follows:
|
|
U.S. Toll Free Number 1-888-286-8010
|
|
|
International Dial-in Number 1-617-801-6888
|
Passcode: 10798661
About China Medical Technologies, Inc.
China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ
Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers,
diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits
to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors.
For more information, please visit
http://www.chinameditech.com
.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as will,
expects, anticipates, future, intends, plans, believes, estimates and similar statements. Among other things, the quotations from management in this press release,
as well as its outlook for 3Q FY2010 and full year FY2010, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.
Further information regarding these and other risks is included in the Companys filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any
forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
Contacts
Sam Tsang and Winnie Yam
Tel:
852-2511-9808
Email:
IR@chinameditech.com
China Medical Technologies, Inc.
Unaudited Condensed Consolidated Balance Sheets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of
|
|
|
|
March 31, 2010
|
|
|
June 30, 2010
|
|
|
September 30, 2010
|
|
|
|
RMB
|
|
|
RMB
|
|
|
RMB
|
|
|
US$
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
815,453
|
|
|
|
742,340
|
|
|
|
805,901
|
|
|
|
120,455
|
|
Trade accounts receivable, net
|
|
|
303,368
|
|
|
|
311,282
|
|
|
|
333,123
|
|
|
|
49,791
|
|
Inventories
|
|
|
24,889
|
|
|
|
20,177
|
|
|
|
21,351
|
|
|
|
3,191
|
|
Prepayments and other receivables
|
|
|
21,508
|
|
|
|
12,048
|
|
|
|
19,093
|
|
|
|
2,854
|
|
Due from a related party
|
|
|
204,774
|
|
|
|
203,445
|
|
|
|
200,715
|
|
|
|
30,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
1,369,992
|
|
|
|
1,289,292
|
|
|
|
1,380,183
|
|
|
|
206,291
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
|
155,825
|
|
|
|
151,621
|
|
|
|
147,355
|
|
|
|
22,024
|
|
Land use rights
|
|
|
7,049
|
|
|
|
7,001
|
|
|
|
6,954
|
|
|
|
1,039
|
|
Goodwill
|
|
|
8,654
|
|
|
|
8,654
|
|
|
|
8,654
|
|
|
|
1,293
|
|
Intangible assets, net
|
|
|
3,285,190
|
|
|
|
3,216,535
|
|
|
|
3,128,820
|
|
|
|
467,651
|
|
Convertible notes issuance costs
|
|
|
46,681
|
|
|
|
39,166
|
|
|
|
34,782
|
|
|
|
5,199
|
|
Share lending costs
|
|
|
35,678
|
|
|
|
30,744
|
|
|
|
27,905
|
|
|
|
4,171
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
|
4,909,069
|
|
|
|
4,743,013
|
|
|
|
4,734,653
|
|
|
|
707,668
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Trade accounts payable
|
|
|
20,126
|
|
|
|
24,136
|
|
|
|
43,958
|
|
|
|
6,570
|
|
Accrued liabilities and other payables
|
|
|
183,498
|
|
|
|
186,036
|
|
|
|
173,693
|
|
|
|
25,960
|
|
Income taxes payable
|
|
|
57,529
|
|
|
|
56,518
|
|
|
|
59,334
|
|
|
|
8,869
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
261,153
|
|
|
|
266,690
|
|
|
|
276,985
|
|
|
|
41,399
|
|
|
|
|
|
|
Convertible notes
|
|
|
2,777,086
|
|
|
|
2,556,014
|
|
|
|
2,528,848
|
|
|
|
377,976
|
|
Deferred income taxes
|
|
|
67,134
|
|
|
|
72,518
|
|
|
|
78,408
|
|
|
|
11,720
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
3,105,373
|
|
|
|
2,895,222
|
|
|
|
2,884,241
|
|
|
|
431,095
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ordinary shares US$0.1 par value: 500,000,000 authorized; 322,680,001 issued and outstanding as of March 31,
2010, June 30, 2010 and September 30, 2010
|
|
|
258,840
|
|
|
|
258,840
|
|
|
|
258,840
|
|
|
|
38,688
|
|
Additional paid-in capital
|
|
|
808,221
|
|
|
|
820,778
|
|
|
|
830,016
|
|
|
|
124,058
|
|
Treasury stock
|
|
|
(45,143
|
)
|
|
|
(47,108
|
)
|
|
|
(47,108
|
)
|
|
|
(7,041
|
)
|
Accumulated other comprehensive loss
|
|
|
(70,556
|
)
|
|
|
(70,731
|
)
|
|
|
(74,412
|
)
|
|
|
(11,122
|
)
|
Retained earnings
|
|
|
852,334
|
|
|
|
886,012
|
|
|
|
883,076
|
|
|
|
131,990
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total shareholders equity
|
|
|
1,803,696
|
|
|
|
1,847,791
|
|
|
|
1,850,412
|
|
|
|
276,573
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and shareholders equity
|
|
|
4,909,069
|
|
|
|
4,743,013
|
|
|
|
4,734,653
|
|
|
|
707,668
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
China Medical Technologies, Inc.
Unaudited Condensed Consolidated Statements of Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended
|
|
|
|
September 30, 2009
|
|
|
June 30, 2010
|
|
|
September 30, 2010
|
|
|
|
RMB
|
|
|
RMB
|
|
|
RMB
|
|
|
US$
|
|
|
|
As adjusted (4)
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands except for per ADS information)
|
|
|
|
|
|
|
Revenues, net (1)
|
|
|
166,066
|
|
|
|
186,170
|
|
|
|
201,834
|
|
|
|
30,167
|
|
Cost of revenues (2)
|
|
|
(57,517
|
)
|
|
|
(61,354
|
)
|
|
|
(90,477
|
)
|
|
|
(13,523
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
108,549
|
|
|
|
124,816
|
|
|
|
111,357
|
|
|
|
16,644
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development (2)
|
|
|
(9,500
|
)
|
|
|
(10,632
|
)
|
|
|
(10,877
|
)
|
|
|
(1,625
|
)
|
Sales and marketing (2)
|
|
|
(17,432
|
)
|
|
|
(18,266
|
)
|
|
|
(21,473
|
)
|
|
|
(3,209
|
)
|
General and administrative (2)
|
|
|
(45,130
|
)
|
|
|
(25,149
|
)
|
|
|
(25,048
|
)
|
|
|
(3,744
|
)
|
Amortization of SPR intangible assets
|
|
|
(27,357
|
)
|
|
|
(27,329
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses
|
|
|
(99,419
|
)
|
|
|
(81,376
|
)
|
|
|
(57,398
|
)
|
|
|
(8,578
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
9,130
|
|
|
|
43,440
|
|
|
|
53,959
|
|
|
|
8,066
|
|
Interest income
|
|
|
2,196
|
|
|
|
4,597
|
|
|
|
5,119
|
|
|
|
765
|
|
Interest expense convertible notes
|
|
|
(35,439
|
)
|
|
|
(32,505
|
)
|
|
|
(32,019
|
)
|
|
|
(4,786
|
)
|
Interest expense amortization of convertible notes issuance costs
|
|
|
(4,381
|
)
|
|
|
(4,012
|
)
|
|
|
(3,906
|
)
|
|
|
(584
|
)
|
Interest expense amortization of share lending costs
|
|
|
(2,756
|
)
|
|
|
(2,475
|
)
|
|
|
(2,456
|
)
|
|
|
(367
|
)
|
Other (expense) income, net
|
|
|
(255
|
)
|
|
|
43,295
|
|
|
|
(1,802
|
)
|
|
|
(269
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income tax
|
|
|
(31,505
|
)
|
|
|
52,340
|
|
|
|
18,895
|
|
|
|
2,825
|
|
Income tax expense
|
|
|
(18,343
|
)
|
|
|
(18,662
|
)
|
|
|
(21,831
|
)
|
|
|
(3,263
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
(49,848
|
)
|
|
|
33,678
|
|
|
|
(2,936
|
)
|
|
|
(438
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per ADS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- basic
|
|
|
(1.89
|
)
|
|
|
1.30
|
|
|
|
(0.11
|
)
|
|
|
(0.02
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- diluted (3)
|
|
|
(1.89
|
)
|
|
|
1.29
|
|
|
|
(0.11
|
)
|
|
|
(0.02
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of ADS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- basic
|
|
|
26,432,974
|
|
|
|
26,005,975
|
|
|
|
26,117,308
|
|
|
|
26,117,308
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- diluted (3)
|
|
|
26,432,974
|
|
|
|
26,128,403
|
|
|
|
26,117,308
|
|
|
|
26,117,308
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RMB000
|
|
|
RMB000
|
|
|
RMB000
|
|
|
US$000
|
|
|
|
|
|
|
- Molecular diagnostic systems
|
|
|
89,233
|
|
|
|
108,092
|
|
|
|
118,347
|
|
|
|
17,689
|
|
- Immunodiagnostic systems
|
|
|
76,833
|
|
|
|
78,078
|
|
|
|
83,487
|
|
|
|
12,478
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
166,066
|
|
|
|
186,170
|
|
|
|
201,834
|
|
|
|
30,167
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Molecular diagnostic systems
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- HPV-DNA chips
|
|
|
|
|
|
|
18
|
|
|
|
3,802
|
|
|
|
568
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2)
|
Stock compensation expense
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RMB000
|
|
|
RMB000
|
|
|
RMB000
|
|
|
US$000
|
|
|
|
|
|
|
- Cost of revenues
|
|
|
|
|
|
|
52
|
|
|
|
117
|
|
|
|
18
|
|
- Research and development
|
|
|
1,256
|
|
|
|
1,418
|
|
|
|
1,145
|
|
|
|
171
|
|
- Sales and marketing
|
|
|
|
|
|
|
91
|
|
|
|
204
|
|
|
|
30
|
|
- General and administrative
|
|
|
6,098
|
|
|
|
9,031
|
|
|
|
7,772
|
|
|
|
1,162
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,354
|
|
|
|
10,592
|
|
|
|
9,238
|
|
|
|
1,381
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3)
|
Interest expense and amortization in connection with convertible notes were not added back in computing diluted earnings per ADS because they were anti-dilutive.
|
(4)
|
As a result of the adoption of new authoritative guidance governing the accounting for own-share lending arrangements in contemplation of convertible debt issuance or
other financing effective on April 1, 2010, the Company adjusted relevant numbers in the unaudited condensed consolidated statements of income for the three months ended September 30, 2009 retrospectively in accordance with GAAP.
|
China Medical Technologies, Inc.
Unaudited Condensed Consolidated Statements of Cash Flows
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended
|
|
|
|
September 30, 2009
|
|
|
June 30, 2010
|
|
|
September 30, 2010
|
|
|
|
RMB
|
|
|
RMB
|
|
|
RMB
|
|
|
US$
|
|
|
|
(in thousands)
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
45,472
|
|
|
|
69,847
|
|
|
|
67,303
|
|
|
|
10,059
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
(357,165
|
)
|
|
|
(1,289
|
)
|
|
|
(1,244
|
)
|
|
|
(186
|
)
|
|
|
|
|
|
Net cash provided by (used in) financing activities
|
|
|
1,011
|
|
|
|
(144,537
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect of foreign currency exchange rate change on cash
|
|
|
(155
|
)
|
|
|
2,866
|
|
|
|
(2,498
|
)
|
|
|
(372
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
(310,837
|
)
|
|
|
(73,113
|
)
|
|
|
63,561
|
|
|
|
9,501
|
|
Cash and cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At beginning of period
|
|
|
1,547,533
|
|
|
|
815,453
|
|
|
|
742,340
|
|
|
|
110,954
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At end of period
|
|
|
1,236,696
|
|
|
|
742,340
|
|
|
|
805,901
|
|
|
|
120,455
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
China Medical Technologies, Inc.
Reconciliations of GAAP measures to Non-GAAP measures
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended
|
|
|
|
September 30, 2009
|
|
|
June 30, 2010
|
|
|
September 30, 2010
|
|
|
|
RMB
|
|
|
RMB
|
|
|
RMB
|
|
|
US$
|
|
|
|
As adjusted (2)
|
|
|
|
|
|
|
|
|
|
|
|
|
(in thousands except for per ADS information)
|
|
Gross profit
|
|
|
108,549
|
|
|
|
124,816
|
|
|
|
111,357
|
|
|
|
16,644
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock compensation expense
|
|
|
|
|
|
|
52
|
|
|
|
117
|
|
|
|
18
|
|
Amortization of acquired intangible assets
|
|
|
22,430
|
|
|
|
22,414
|
|
|
|
49,422
|
|
|
|
7,386
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP gross profit
|
|
|
130,979
|
|
|
|
147,282
|
|
|
|
160,896
|
|
|
|
24,048
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross margin
|
|
|
65.4
|
%
|
|
|
67.0
|
%
|
|
|
55.2
|
%
|
|
|
55.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP gross margin
|
|
|
78.9
|
%
|
|
|
79.1
|
%
|
|
|
79.7
|
%
|
|
|
79.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
9,130
|
|
|
|
43,440
|
|
|
|
53,959
|
|
|
|
8,066
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock compensation expense
|
|
|
7,354
|
|
|
|
10,592
|
|
|
|
9,238
|
|
|
|
1,381
|
|
Amortization of acquired intangible assets
|
|
|
49,787
|
|
|
|
49,743
|
|
|
|
49,422
|
|
|
|
7,386
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP operating income
|
|
|
66,271
|
|
|
|
103,775
|
|
|
|
112,619
|
|
|
|
16,833
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating margin
|
|
|
5.5
|
%
|
|
|
23.3
|
%
|
|
|
26.7
|
%
|
|
|
26.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP operating margin
|
|
|
39.9
|
%
|
|
|
55.7
|
%
|
|
|
55.8
|
%
|
|
|
55.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
(49,848
|
)
|
|
|
33,678
|
|
|
|
(2,936
|
)
|
|
|
(438
|
)
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock compensation expense
|
|
|
7,354
|
|
|
|
10,592
|
|
|
|
9,238
|
|
|
|
1,381
|
|
Amortization of acquired intangible assets
|
|
|
49,787
|
|
|
|
49,743
|
|
|
|
49,422
|
|
|
|
7,386
|
|
Non-cash interest expense of convertible notes
|
|
|
7,621
|
|
|
|
7,916
|
|
|
|
7,221
|
|
|
|
1,079
|
|
Non-cash interest expense amortization of share lending costs
|
|
|
2,756
|
|
|
|
2,475
|
|
|
|
2,456
|
|
|
|
367
|
|
Gain on purchase of convertible notes
|
|
|
|
|
|
|
(47,393
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP net income
|
|
|
17,670
|
|
|
|
57,011
|
|
|
|
65,401
|
|
|
|
9,775
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net margin
|
|
|
|
|
|
|
18.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP net margin
|
|
|
10.6
|
%
|
|
|
30.6
|
%
|
|
|
32.4
|
%
|
|
|
32.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
(49,848
|
)
|
|
|
33,678
|
|
|
|
(2,936
|
)
|
|
|
(438
|
)
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
(2,196
|
)
|
|
|
(4,597
|
)
|
|
|
(5,119
|
)
|
|
|
(765
|
)
|
Interest expense convertible notes
|
|
|
35,439
|
|
|
|
32,505
|
|
|
|
32,019
|
|
|
|
4,786
|
|
Interest expense amortization of convertible notes issuance costs
|
|
|
4,381
|
|
|
|
4,012
|
|
|
|
3,906
|
|
|
|
584
|
|
Interest expense amortization of share lending costs
|
|
|
2,756
|
|
|
|
2,475
|
|
|
|
2,456
|
|
|
|
367
|
|
Income tax expense
|
|
|
18,343
|
|
|
|
18,662
|
|
|
|
21,831
|
|
|
|
3,263
|
|
Depreciation
|
|
|
5,521
|
|
|
|
5,475
|
|
|
|
5,497
|
|
|
|
822
|
|
Amortization of acquired intangible assets
|
|
|
49,787
|
|
|
|
49,743
|
|
|
|
49,422
|
|
|
|
7,386
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA
|
|
|
64,183
|
|
|
|
141,953
|
|
|
|
107,076
|
|
|
|
16,005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA margin
|
|
|
38.6
|
%
|
|
|
76.2
|
%
|
|
|
53.1
|
%
|
|
|
53.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA
|
|
|
64,183
|
|
|
|
141,953
|
|
|
|
107,076
|
|
|
|
16,005
|
|
Adjustments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock compensation expense
|
|
|
7,354
|
|
|
|
10,592
|
|
|
|
9,238
|
|
|
|
1,381
|
|
Gain on purchase of convertible notes
|
|
|
|
|
|
|
(47,393
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA
|
|
|
71,537
|
|
|
|
105,152
|
|
|
|
116,314
|
|
|
|
17,386
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA margin
|
|
|
43.1
|
%
|
|
|
56.5
|
%
|
|
|
57.6
|
%
|
|
|
57.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings (loss) per ADS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- basic
|
|
|
(1.89
|
)
|
|
|
1.30
|
|
|
|
(0.11
|
)
|
|
|
(0.02
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- diluted
|
|
|
(1.89
|
)
|
|
|
1.29
|
|
|
|
(0.11
|
)
|
|
|
(0.02
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-GAAP earnings per ADS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- basic
|
|
|
0.67
|
|
|
|
2.19
|
|
|
|
2.50
|
|
|
|
0.37
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- diluted (1)
|
|
|
0.67
|
|
|
|
2.18
|
|
|
|
2.50
|
|
|
|
0.37
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of ADS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- basic
|
|
|
26,432,974
|
|
|
|
26,005,975
|
|
|
|
26,117,308
|
|
|
|
26,117,308
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- diluted (1)
|
|
|
26,432,974
|
|
|
|
26,128,403
|
|
|
|
26,117,308
|
|
|
|
26,117,308
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notes:
(1)
|
Interest expense and amortization in connection with convertible notes were not added back in computing non-GAAP diluted earnings per ADS because they were
anti-dilutive.
|
(2)
|
As a result of the adoption of new authoritative guidance governing the accounting for own-share lending arrangements in contemplation of convertible debt issuance or
other financing effective on April 1, 2010, the Company adjusted relevant numbers in the unaudited condensed consolidated statements of income for the three months ended September 30, 2009 retrospectively in accordance with GAAP.
|
China Medical (NASDAQ:CMED)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Medical (NASDAQ:CMED)
Historical Stock Chart
From Jul 2023 to Jul 2024